Navigation Links
FDA Reviews Side Effects From Prostate Cancer Therapy

Doctors urged to consider risks of hormone treatment, inform patients

MONDAY, May 3 (HealthDay News) -- A widely used class of prostate cancer drugs called gonadotropin-releasing hormone (GnRH) agonists increases the risk of diabetes, heart attack, stroke and sudden death in men, a U.S. Food and Drug Administration review has found.

Based on initial findings from a preliminary and ongoing analysis of several studies, the FDA says doctors should be aware of the potential risks of GnRH agonists, and carefully consider the benefits and risks of these drugs when deciding on treatment for prostate cancer patients.

The agency also recommended that:

  • Patients taking GnRH agonists should be checked regularly for signs of the development of diabetes and cardiovascular disease.
  • Management of cardiovascular risk factors -- including smoking, as well as increases in blood pressure, cholesterol, blood sugar and weight -- should be stressed.
  • Those taking GnRH agonists should not stop the therapy unless instructed by their health-care provider.

Drugs in the GnRH agonist class include Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic products. These drugs suppress production of testosterone, a hormone involved in the growth of prostate cancer.

"While our review of these prostate cancer treatments is ongoing and there are some limitations to the data, FDA believes it is important to tell patients and health-care professionals that there may be an increased risk of serious side effects," Dr. Robert Justice, director of the drug oncology products division at FDA's Center for Drug Evaluation and Research, said in a news release.

Some GnRH agonists are also used to treat conditions in women and children.

More information

The U.S. National Cancer Institute has more about prostate cancer treatments.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, May 3, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Hollywood Eco-Celebrity Rachelle Carson-Begley Gives Skincare Company Bella V Rave Reviews
3. WebLOQ Selected By MARSI to Streamline Medical Audit Reviews From Dispersed Healthcare Community
4. New Book Reviews Core Competencies for Pharmacy Leaders
5. HCA Previews Fourth Quarter and Year-End 2009 Results
6. Hearing Aid Reviews Go Public on Advice on Hearing Aids
7. Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill
8. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
9. Finding cancer cold spots can help minimize radiotherapy side-effects
10. Adverse drug effects in epileptic patients not correlated with number of prescribed medications
11. Most women facing gynecologic surgery dont worry about its effects on sex
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: